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Summary
The assessment of the presence of eosinophilic airway inﬂammation may help in
predicting the steroid response in subjects with respiratory symptoms. Unlike
patients with asthma, only a subset of patients with chronic obstructive pulmonary
disease (COPD) beneﬁts from steroid treatment. Fractional exhaled nitric oxide
(FENO) is a useful surrogate marker for eosinophilic airway inﬂammation, but data
on the repeatability of FENO measurements in COPD needed for the assessment of
signiﬁcant change are insufﬁcient. The aim of this study was to assess the short-term
repeatability of FENO measurement in subjects with moderate to very severe chronic
airway obstruction compared to that in healthy subjects. We studied 20 patients with
stable COPD and 20 healthy subjects, and determined FENO (ﬂow rate 50 ml s
)1)
three times: at baseline, 10 min and 24 h after baseline. Spirometry was performed
on the ﬁrst study day after the FENO measurements. The median FENO
concentration in patients with COPD was 15Æ6 ppb, and in healthy subjects,
15Æ2 ppb. The coefﬁcient of variation (CoV) for 24-h measurements was 12Æ4% in
COPD patients, and 15Æ9% in healthy subjects. Among COPD patients with global
initiative for chronic obstructive lung disease stage 2 disease, the CoV was 13Æ7%,
and among those with stage 3–4 disease, 10Æ5%. The ﬁndings indicate that the short-
term repeatability of FENO measurement in patients with moderate to very severe
COPD is equally good as in healthy subjects. A change in FENO exceeding 24% is
likely to reﬂect a minimum measurable change in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by airﬂow limitation which is not fully reversible and is usually
progressive. Airway inﬂammation in COPD is dominated by
neutrophils and is generally unresponsive to inhaled steroids.
Eosinophilia is present in a subset of patients and is often more
pronounced during exacerbations (Sutherland & Martin, 2003).
COPD patients with frequent exacerbations have been shown to
beneﬁt from inhaled steroids (Rabe et al., 2007).
Fractional exhaled nitric oxide (FENO) is considered a reliable
surrogate marker for eosinophilic airway inﬂammation and has
proved useful in the diagnosis of asthma (Taylor et al., 2006).
FENO levels in COPD vary from low to elevated (Barnes et al.,
2006), likely reﬂecting the heterogeneity of the disease and the
FENO-reducing effect of smoking. However, differential diag-
nosis between asthma and COPD is not always clear cut; the
clinical course of asthma sometimes leads to ﬁxed airway
obstruction, and partial reversibility may be present in COPD.
Partial reversibility has been reported to associate with increased
FENO and sputum eosinophilia (Papi et al., 2000), and the
presence of eosinophilic airway inﬂammation in COPD, as
veriﬁed either by induced sputum or elevated FENO, has been
shown to correlate with the steroid response (Brightling et al.,
2000; Zietkowski et al., 2005; Leigh et al., 2006; Kunisaki et al.,
2008). A response to steroids may result in an improvement of
symptoms and lung function and in a reduction of exacerbation
frequency (Rabe et al., 2007), making the identiﬁcation of
potential steroid responders important in clinical practice.
The repeatability of FENO measurements has been proven to
be good in healthy subjects (Ekroos et al., 2000; Kharitonov
et al., 2003), in both non-smokers and smokers (Bohadana et al.,
2008), in patients with asthma (Ekroos et al., 2002; Kharitonov
et al., 2003) and in subjects with respiratory symptoms (Ekroos
et al., 2002). Good repeatability has been reported also in
patients with COPD (Brindicci et al., 2005; Bhowmik et al.,
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could impair the repeatability, because the requirement of
constant respiratory ﬂow for at least 6 s might not be easy to
fulﬁl; these studies have included only a small number of such
patients.
The aim of this study was to assess the short-term
repeatability of FENO in subjects with moderate to very severe
chronic obstructive pulmonary disease compared to that in
healthy subjects.
Methods
Study population
Twenty patients with previously diagnosed COPD were
recruited from the outpatient department of the Division of
Respiratory Diseases and from the Research Unit for Respiratory
Diseases of the Helsinki University Central Hospital. COPD
diagnosis was veriﬁed with information available from sub-
jects  hospital records (mean 5 years since diagnosis, range
1–12 years). All subjects had forced expiratory volume in 1 s
(FEV1) <80% of predicted (Viljanen et al., 1982) and the ratio
of FEV1 to forced vital capacity (FVC) of <0Æ7. The chosen
inclusion criteria required the subjects to be ex-smokers (mean
52 pack-years, range 20–100) who had stopped smoking at least
1 year ago (mean 6 years, range 1–21 years) and who were
clinically stable with no changes in their medication during the
preceding 4 weeks. The subjects continued their regular
medication, with the exception of short-acting beta-agonists
(SABA), which were withheld for 12 h prior to the measure-
ments. Of the study subjects, 11 (58%) used inhaled corticos-
teroids (ICS), and ten of these used ICS in combination with
long-acting beta-agonists (LABA), whereas one used LABA
without ICS. Nine subjects (47%) used long-acting anticoliner-
gic (tiotropium), and none used short-acting anticolinergics.
Two subjects used teophylline, and one subject used leukotriene
receptor antagonist in addition to other medication. Nine
subjects used SABA as rescue medication. Four subjects (21%)
had no medication for COPD. Of the 19 patients, six had no
comorbidities, ten patients received medication for hyperten-
sion, three for coronary heart disease, three for hypercholester-
olemia, two for diabetes and two for rheumatoid arthritis. The
20 healthy subjects were recruited from the hospital staff and
their relatives. None had a history or symptoms of respiratory
diseases, and all were either life-time non-smokers or had
smoked a maximum of ﬁve pack-years, but had stopped
smoking at least 5 years ago. All subjects were free of respiratory
infections for the preceding 4 weeks. The anthropometric and
spirometric characteristics as well as data on the smoking history
of the study population appear in Table 1.
Study design
FENO was determined three times: at baseline, 10 min and 24 h
after baseline. Spirometry was carried out on the ﬁrst study day
after the FENO measurements. The FENO measurements were
taken in the Laboratory of Clinical Physiology and spirometry in
the Research Unit for Pulmonary Diseases by experienced study
nurses. This study was approved by the Ethics Committee of the
Department of Medicine at the Helsinki University Central
Hospital. All subjects provided their written informed consent.
Fractional exhaled nitric oxide measurement
FENO was measured with a chemiluminescence analyser
(Sievers 270B, Boulder, CO, USA) by using computer software
specially developed for this purpose (Ekroos et al., 2000). Two-
point calibration of the analyser was performed daily before the
FENO measurements. Expiratory airﬂow and exhaled volume
were measured with a pneumotachograph (Baby Pneumotach-
ograph, Erich Jaeger GmbH, Wurzburg, Germany) simulta-
neously with FENO in real time. The exhalation procedure
Table 1 Characteristics of the populations studied.
Healthy subjects (n = 20) All COPD (n = 19) COPD stage 2 (n = 12) COPD stage 3–4 (n =7 )
Gender m⁄f (n) 5⁄15 13⁄67 ⁄56 ⁄1
Age, years 41 (23–58) 65 (54–72) 67 (54–72) 63 (55–69)
Height, cm 168Æ3 (153–184) 171Æ5 (151–190) 168Æ8 (158–180) 176Æ0 (151–190)
Weight, kg 70Æ8 (50–92) 82Æ6 (47–114) 87Æ8 (57–114) 73Æ7 (47–100)
Body mass index, kg m
)2 24Æ9 (21Æ1–30Æ5) 28Æ1 (20Æ6–43Æ3) 30Æ8 (21Æ7–43Æ3) 23Æ5 (20Æ6–27Æ7)
FVC, l 4Æ4( 3 Æ1–5Æ8) 3Æ5( 1 Æ8–4Æ7) 3Æ3( 1 Æ9–4Æ7) 3Æ7( 1 Æ8–4Æ7)
FVC, % of predicted
a 103Æ1 (86Æ5–135Æ5) 87Æ5 (67Æ8–125Æ2) 89Æ9 (72Æ2–125Æ2) 83Æ3 (67Æ8–95Æ4)
FEV1, l 3Æ5( 2 Æ4–4Æ8) 1Æ7( 0 Æ5–2Æ9) 1Æ9( 1 Æ1–2Æ9) 1Æ3( 0 Æ5–1Æ8)
FEV1, % of predicted
a 98Æ6 (78Æ4–124Æ7) 53Æ0 (23Æ1–79Æ7) 62Æ5 (50Æ5–79Æ7) 36Æ6 (23Æ1–46Æ9)
FEV1⁄FVC 0Æ79 (0Æ72–0Æ92) 0Æ49 (0Æ28–0Æ66) 0Æ57 (0Æ34–0Æ66) 0Æ35 (0Æ28–0Æ41)
GOLD stage 2⁄3⁄4( n)N A 1 2 ⁄5⁄21 2 ⁄0⁄00 ⁄5⁄2
Pack years NA 52 (20–100) 49 (20–100) 57 (30–100)
Parameters expressed as mean (range) unless otherwise stated.
COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; GOLD, global initiative for chronic
obstructive lung disease; NA, not applicable.
aFinnish reference values (Viljanen et al., 1982).
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27fulﬁlled the criteria deﬁned in the American Thoracic Soci-
ety⁄European Respiratory Society guidelines on exhaled FENO
measurements (ATS⁄ERS 2005). On both study days, the
subjects rinsed their mouths with sodium bicarbonate solution
(Hartwall Novelle
 , Oy Hartwall Ab, Helsinki, Finland) prior to
the ﬁrst measurement, to eliminate any nitric oxide produced in
the mouth. After the inhalation of synthetic NO-free air, subjects
exhaled from total lung capacity with a ﬂow rate of 50 ml s
)1
against a ﬂow resistor (model #7100R, 200 cmH20l
)1 s
)1,
ﬂow range 0–0Æ1ls
)1; Hans Rudolph, Shawnee, KS, USA). No
nose clips were used. The subjects maintained the required ﬂow
rate with the aid of visual feedback from the computer screen.
An acceptable measurement had a mean ﬂow rate between 0Æ045
and 0Æ055 l s
)1 and a duration of exhalation of at least 10 s. The
mean value taken from a 3-s period during the end-exhaled NO
plateau was recorded for analysis. At least three successive FENO
measurements were taken, and their mean values were recorded
for analysis. An acceptable coefﬁcient of variation (CoV) for the
successive FENO determinations was £10%.
Spirometry
Spirometry was completed using a ﬂow-volume device (VMax
20c; Sensor Medics, Yorba Linda, CA, USA) with the subject
seated according to ATS⁄ERS 2005 criteria (Miller et al., 2005;
Pellegrino et al., 2005). The spirometry variables analysed were
FVC, FEV1 and FEV1⁄FVC. Published Finnish reference values
were used (Viljanen et al., 1982).
Statistical analysis
Statistical analyses were performed with SPSS version 15.0 for
Windows (SPSS, Chicago, IL, USA). FENO results are expressed
as medians (25–75% quartiles), and non-parametric tests were
applied, as FENO values are not normally distributed and the
small number of measurements would otherwise be sensitive to
the effect of single outliers. Bland–Altman plots served to
illustrate the repeatability and intra-subject correlation of FENO
measurements (Bland & Altman, 1986; Chinn, 1991); 95% of
the differences between measurements were expected to lie
within two standard deviations (SD). Intraclass correlation
coefﬁcients (ICC) with 95% conﬁdence intervals were calcu-
lated, and ICC-values >0Æ6 were considered clinically signiﬁcant
(Faul et al., 1999). The ICC is an application of analysis of
variance that produces the measures of consistency or agreement
of values within cases (Shrout & Fleiss, 1979; McGraw & Wong,
1996). Coefﬁcients of variation (CoV) were calculated for
intrasession and between-session repeatability by dividing the
SD of the individual measurements by their mean, expressed as
percentages. Wilcoxon s pairwise test was used for paired
observations. A P-value of <0Æ05 was considered statistically
signiﬁcant.
Results
Of the 20 patients with COPD studied, 12 had moderate COPD
[global initiative for chronic obstructive lung disease (GOLD)
stage 2, FEV1 < 80% but ‡50%], ﬁve had severe COPD (GOLD
stage 3, FEV1 < 50% but ‡30%) and three had very severe
COPD (GOLD stage 4, FEV1 < 30%). One subject (woman,
73 years) with stage 4 disease was unable to perform technically
acceptable FENO measurements (intrasession CoV was 10% at
baseline, 18% at 10 min and 19% at 24 h) and thus was
excluded from the analysis. Another subject with stage 4 disease
had a CoV of 11% at the +10-min measurement, with a CoV of
£10% at the baseline and +24-h measurements; the subject was
included in the analyses. One subject (woman, 54 years, stage 2
disease) did not return for the second study day, so +24-h
FENO measurements are available from 18 subjects. All of the
healthy subjects were able to produce technically acceptable
FENO measurements.
Median FENO values for each session (baseline, +10 min and
+24 h), CoV and ICC between baseline and +10-min measure-
ments as well as between baseline and +24-h measurements for
healthy subjects, for all patients with COPD and separately for
COPD patients with stage 2 and stage 3–4 disease appear in
Table 2. Intrasession repeatability for patients with COPD and
healthy subjects ranged from 5Æ5% to 6Æ9%. The between-session
repeatability (baseline and +24-h measurements) of FENO in
patients with COPD and in healthy subjects is presented by
Bland–Altman plots (Fig. 1a,b), where the mean of the baseline
and +24-h FENO values are plotted against the difference
between the FENO values of the two respective sessions.
Median FENO at baseline was 15Æ6 ppb (25–75% quartiles
12Æ8–22Æ5) in patients with COPD and 15Æ2 ppb (10Æ1–21Æ6) in
healthy subjects. In one patient with COPD , the baseline FENO,
Table 2 Median FENO values and their short-term variability in the groups studied.
FENO, ppb
baseline
FENO, ppb
+10 min
CoV*
(%) ICC (95% CI)
FENO, ppb
+24 h
CoV**
(%) ICC (95% CI)
Healthy (n = 20) 15Æ2 (10Æ1–21Æ6) 17Æ4 (10Æ8–26Æ4) 13Æ70 Æ85 (0Æ67–0Æ94) 14Æ5( 7 Æ7–22Æ3) 15Æ90 Æ90 (0Æ77–0Æ96)
COPD (n = 19) 15Æ6 (12Æ8–22Æ5) 19Æ6 (15Æ8–23Æ2) 11Æ00 Æ90 (0Æ77–0Æ96) 15Æ7 (11Æ1–22Æ8) 12Æ40 Æ88 (0Æ72–0Æ95)
GOLD stage 2 (n = 12) 18Æ2 (14Æ5–25Æ7) 20Æ0 (16Æ1–28Æ1) 10Æ90 Æ91 (0Æ74–0Æ97) 15Æ5 (11Æ1–29Æ3) 13Æ70 Æ89 (0Æ65–0Æ97)
GOLD stage 3–4 (n =7 ) 1 3 Æ6( 9 Æ2–18Æ6) 18Æ4( 9 Æ1–20Æ4) 11Æ20 Æ92 (0Æ32–0Æ97) 15Æ9 (11Æ0–20Æ5) 10Æ50 Æ83 (0Æ37–0Æ97)
FENO expressed as medians (25–27% quartiles).
FENO, fractional exhaled nitric oxide; CoV, coefﬁcient of variance (*between baseline and +10 min, **between baseline and +24 h); ICC, intraclass
correlation coefﬁcient; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease.
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2839 ppb, exceeded the upper normal limit of 30 ppb (Rouhos
et al., 2008). No comparison of FENO levels between the studied
groups was performed as the groups were not age- or gender-
matched and all pulmonary medication, including ICS inﬂu-
encing FENO, was allowed. No signiﬁcant difference appeared
between FENO values at baseline and at +24 h among either
patients with COPD or healthy subjects (P =0 Æ62 and P =0 Æ68,
respectively). FENO values at the +10-min measurement (when
the subjects did not rinse their mouths with sodium bicarbon-
ate) in both COPD and healthy subjects were slightly but
signiﬁcantly higher than at the +24-h measurement (P =0 Æ002
and P =0 Æ03, respectively) or at baseline (P =0 Æ008 and
P =0 Æ002).
Discussion
The present study demonstrated that the repeatability of FENO
between successive days in patients with stable COPD is equally
good compared to that in healthy subjects. A coefﬁcient of
variation of 12Æ4% for the FENO measurements performed at a
24-h interval suggests that a change in FENO exceeding 24% is
likely to reﬂect a minimum measurable change of FENO in
COPD.
A coefﬁcient of variation of 12Æ4% in patients with COPD for
the FENO measurements performed at a 24-h interval is in
agreement with the results of the study by Bhowmik et al.
(2005), who reported a CoV of 13Æ1% for the short-term
repeatability of FENO in a group of 79 patients with moderate to
severe COPD, although the ﬂow rate for the FENO measure-
ments (5 l min
)1) differed from current recommendations
(ATS⁄ERS 2005), and the exact interval for repeated measure-
ments was not mentioned. Brindicci et al. (2005) studied the
day-to-day variation as well as the diurnal variation of FENO in
eight COPD patients with stage 2 disease as part of a larger study
of 81 subjects (non-smokers and smokers with or without
airway obstruction) using a multiple ﬂow technique. They
reported a high degree of reproducibility (ICC 0Æ993 for a ﬂow
rate of 50 ml s
)1) in FENO measurements for the whole study
group and concluded that the results are applicable in COPD of
differing severity. In the present study, the repeatability was
equally good in patients with moderate or very severe
obstruction, except for one patient with very severe COPD
who was unable to maintain the ﬂow rate required to produce
repeated FENO recordings that would meet the requirements of
an acceptable measurement. Similarly, 11 of the 98 patients
originally included in Bhowmik s study were unable to perform
acceptable measurements. These subjects were older (mean age
71 years) and had a lower FEV1 (mean 0Æ84 l) than did those
capable of producing technically acceptable measurements
(Bhowmik et al., 2005).
The day-to-day repeatability of FENO using a ﬂow rate of
50 ml s
)1 has been reported to be good in healthy subjects. Our
study found an ICC of 0Æ90 in healthy subjects between FENO
measurements performed 24 h apart to be equal to ICC of 0Æ94
reported by Kharitonov et al. (2003) in a group of ten healthy
non-smoking adults. Repeatability in asthmatics has been
reported to be equally good, with an ICC of 0Æ90 for FENO
measurements performed with a 24-h interval in a group of ten
adults with steroid-naive asthma (Kharitonov et al., 2003).
The results of our study suggest that a change in FENO
concentration exceeding 24% is likely to reﬂect a measurable
change of in the inﬂammatory process in COPD. A recent study
(de Laurentiis et al., 2008) measuring FENO (ﬂow rate
50 ml s
)1) once a month over a period of 1 year in 59 patients
with COPD (mean age 66 years and mean GOLD stage 2Æ6)
found a signiﬁcant correlation between individual exacerbation
rate and FENO CoV, as patients with a FENO CoV of >40%
during the year reported a twofold increase in exacerbation rate
over that of patients with a FENO CoV of <40%.
Because a spirometric manoeuvre may temporarily reduce
FENO (Silkoff et al., 1999) and SABA may temporarily increase
FENO (Silkoff et al., 1999), SABA were withheld for 12 h before
the FENO measurements, and spirometry was performed after
the FENO measurements on the ﬁrst study day. Mouthrinsing
with sodium bicarbonate or chlorhexidine is known to slightly
(a)
(b)
Figure 1 Bland–Altman analysis for the 24 h repeatability of fractional
exhaled nitric oxide in (a) patients with chronic obstructive pulmonary
disease and (b) healthy subjects.
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29reduce FENO levels by eliminating any nitric oxide produced in
the mouth (Zetterquist et al., 1999; Marteus et al., 2005), but the
duration of this effect remains unknown. The subjects in the
present study rinsed their mouths before the ﬁrst FENO
measurements on both study days, but the procedure was not
repeated before the +10-min measurements. This may explain
the slightly higher FENO values in the +10-min measurements
than in the baseline or +24-h measurements, as experience from
our laboratory suggests that the reduction in FENO because of
mouthrinsing may disappear in <10 min (Piirila ¨ P, Rouhos A,
Sovija ¨rvi A. R. A, unpublished data). The staging of the severity
of COPD according to the GOLD criteria should be based on
postbronchodilator FEV1.The present study, however, used
prebronchodilator values for practical reasons. Because the
patients had been diagnosed with COPD on average 5 years
previously and were clinically stable with regular medication, a
signiﬁcant bronchodilator response would be unlikely. To
obtain a patient population representative of a real-life situation,
COPD patients with comorbidities were included as long as they
were clinically stable. The groups studied were not age- or
gender-matched, and healthy subjects were more often women
and younger than patients with COPD. However, older disabled
subjects with airﬂow obstruction performed FENO measure-
ments as well as did the younger healthy ones. The study
included only stable COPD patients: all but one had FENO
within normal limits (£30 ppb). Thus, the results are not
directly applicable to COPD patients with elevated FENO or with
unstable disease, but reﬂect the minimum measurable change of
FENO in COPD.
Unlike patients with asthma, only a subset of patients with
COPD beneﬁt from treatment with ICS. In subjects with ﬁxed or
partially reversible airway obstruction, an elevated sputum
eosinophil count or elevated FENO has been found to relate to
an improvement in FEV1 following steroid treatment (Fabbri
et al., 2003; Brightling et al., 2005; Zietkowski et al., 2005;
Kunisaki et al., 2008;). FENO measurement can thus be useful
in focusing steroid treatment to those most likely to beneﬁt from
it. Because FENO measured with the conventional technique
reﬂects airway inﬂammation mainly in the larger airways, it thus
may not fully represent the more peripheral inﬂammation
present in COPD. This peripheral component of FENO, better
detected by using a technique of multiple ﬂow rates, has been
shown to be insensitive to steroid treatment, however, and thus
may be inapplicable when the purpose of FENO measurement is
to identify possible steroid responders. High level of bronchial
NO ﬂux has been reported to relate to symptom relief and
improvement in FEV1 after steroid treatment, whereas no such
association was detected in relation to alveolar NO (Lehtima ¨ki
et al., 2010).
The ﬁndings of the present study indicate that the short-term
repeatability of FENO is equally good in patients with stable
COPD as in healthy subjects, although in patients with very
severe disease, difﬁculties may arise in maintaining the required
ﬂow rate. The results suggest that a short-term change in FENO
values exceeding 24% is likely to reﬂect a minimum measurable
change in COPD.
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